Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2019 17:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results

SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
January 07, 2019 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus

SAN FRANCISCO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
November 12, 2018 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD

First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a...
November 08, 2018 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update

ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate ...
October 31, 2018 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces November Conference Participation

SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
October 02, 2018 07:05 ET | Source: Assembly Biosciences

Assembly Biosciences Announces Oral Presentation at 2018 AASLD

SAN FRANCISCO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
August 28, 2018 07:05 ET | Source: Assembly Biosciences

Assembly Biosciences to Present at Upcoming Investor Conferences

SAN FRANCISCO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in...
August 08, 2018 16:05 ET | Source: Assembly Biosciences

Assembly Biosciences Announces Second Quarter 2018 Financial Results

- ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 - Strong Balance Sheet Provides Significant Runway SAN FRANCISCO and...
July 25, 2018 07:05 ET | Source: Assembly Biosciences

Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection

INDIANAPOLIS and SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
July 16, 2018 16:05 ET | Source: Assembly Biosciences

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

INDIANAPOLIS and SAN FRANCISCO, July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public...